{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.36","upperLimit":"94.74","value":"86.05"},{"groupId":"OG001","lowerLimit":"68.27","upperLimit":"100","value":"87.5"},{"groupId":"OG002","lowerLimit":"28.53","upperLimit":"66.21","value":"47.37"},{"groupId":"OG003","lowerLimit":"8.04","upperLimit":"37.42","value":"22.73"},{"groupId":"OG004","lowerLimit":"36.03","upperLimit":"67.67","value":"51.85"},{"groupId":"OG005","lowerLimit":"13.61","upperLimit":"40.45","value":"27.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"37"}],"units":"Participants"}],"description":"Three-year EFS estimates and 90% CI will be reported by treatment arm and end-induction MRD status.","dispersionType":"90% Confidence Interval","groups":[{"description":"Arm A, standard risk MLL-G","id":"OG000","title":"Arm A (MRD Negative)"},{"description":"Arm A, standard risk MLL-G","id":"OG001","title":"Arm A (MRD Positive)"},{"description":"Arm B, IR/HR MLL-R chemotherapy","id":"OG002","title":"Arm B (MRD Negative)"},{"description":"Arm B, IR/HR MLL-R chemotherapy","id":"OG003","title":"Arm B (MRD Positive)"},{"description":"Arm C, IR/HR MLL-R chemotherapy and lestaurtinib","id":"OG004","title":"Arm C (MRD Negative)"},{"description":"Arm C, IR/HR MLL-R chemotherapy and lestaurtinib","id":"OG005","title":"Arm C (MRD Positive)"}],"paramType":"NUMBER","populationDescription":"Patients who had data collected","reportingStatus":"POSTED","timeFrame":"3 Years from end of Induction)","title":"Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm","type":"SECONDARY","unitOfMeasure":"percent probability"}